Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

PT Dilution

Immunology & Autoimmune

Prothrombin Time Dilution StudyPT dil

Review status

Currently under review

Pending specialist review and validation.

What it shows

PT Dilution is a specialized version of the prothrombin time test that helps clarify why a clotting time is longer than expected. The standard prothrombin time measures how quickly your blood forms a clot through the tissue factor pathway. The dilution study repeats the measurement after diluting your plasma in specific ways to see whether the prolongation is due to missing clotting factors or an interfering substance in the blood.

Clinicians use this test when a routine clotting test is abnormal or does not fit with your clinical picture. By observing how the result behaves after dilution, the laboratory can separate true factor problems from inhibitors that interfere with the assay, improving the accuracy of the workup.

Why it matters

Understanding the cause of a prolonged clotting time guides safe care. PT Dilution can point toward issues such as factor deficiencies from liver disease or vitamin K problems, or toward the presence of inhibitors like antiphospholipid antibodies or medication effects. This helps your team decide on appropriate treatment, monitoring, and any needed precautions before procedures.

Your clinician may order this test if you have unusual bleeding or bruising, a history of blood clots, or if you take blood thinners. It is also useful when prior results are inconsistent, ensuring that decisions are based on the most reliable information possible.

Understanding your results

Results are interpreted by looking at how the clotting time responds to dilution. If results move closer to typical expectations, it can suggest a shortage of clotting factors. If results remain prolonged despite dilution, it can suggest an inhibitor such as antiphospholipid antibodies or the effect of certain medicines. Your doctor will consider these patterns together with your history, exam, and other labs.

If your result suggests an inhibitor or a factor problem, follow up may include specific factor testing, antiphospholipid antibody studies, review of medicines and supplements, or evaluation for liver or nutritional issues. Do not change or stop any medication unless your clinician advises it, and share a full list of prescriptions, over the counter products, and supplements.

Reference ranges

12.415 s
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact PT Dilution

  • Anticoagulant medications

    Warfarin and some newer oral anticoagulants can prolong clotting tests and may mimic an inhibitor pattern. Always provide a complete medication list before blood draw.

  • Specimen collection and handling

    Underfilled citrate tubes, high hematocrit, clots in the tube, or delayed processing can artifactually prolong results. Proper fill and prompt lab handling reduce errors.

  • Liver function and vitamin K status

    Liver disease or low vitamin K can lower clotting factor levels, leading to prolongation that may correct with dilution. Dietary changes or antibiotics can also play a role.

  • Antiphospholipid antibodies

    These antibodies can interfere with clotting tests and may prevent correction with dilution. Further testing for antiphospholipid syndrome may be recommended.

  • Heparin contamination

    Sample contamination from heparinized lines can prolong clotting times and confuse interpretation. Drawing from a peripheral vein after proper line clearing helps avoid this.

  • Recent transfusion

    Transfused plasma or red cells can temporarily change clotting factor levels and influence how results behave after dilution. Share any recent transfusion history.

  • Pregnancy and hormonal therapies

    Physiologic changes in pregnancy and use of estrogen containing therapies can alter coagulation testing and may affect interpretation of a dilution study.

2026

References

  1. McGill University Health Centre. (2021, June 09). PT Dilution (Task CD 700675). Laboratory reference ranges.
  2. Clinical and Laboratory Standards Institute. (2014). One-stage prothrombin time and activated partial thromboplastin time test; approved guideline (H47-A2). CLSI.
  3. Pengo, V., Tripodi, A., Reber, G., Rand, J. H., Ortel, T. L., Galli, M., & de Groot, P. G. (2009). Update of the guidelines for lupus anticoagulant detection. Journal of Thrombosis and Haemostasis, 7(10), 1737–1740.